Skip to main content
Erschienen in: Rheumatology International 1/2021

02.08.2020 | Review

Immune checkpoint inhibitor-induced musculoskeletal manifestations

verfasst von: Foteini Angelopoulou, Dimitrios Bogdanos, Theodoros Dimitroulas, Lazaros Sakkas, Dimitrios Daoussis

Erschienen in: Rheumatology International | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Immune checkpoint inhibitors (ICI) associate with a wide range of immune-related adverse events (Ir-AE), including musculoskeletal manifestations. We aimed at identifying all studies reporting musculoskeletal Ir-AE. An electronic (Medline, Scopus and Web of Science) search was performed using two sets of key words. The first set consisted of: arthritis, musculoskeletal, polymyalgia rheumatica and myositis. The second set consisted of: anti-PD-1, anti-PD-L1, anti-CTLA-4, ipilimumab, tremelimumab, pembrolizumab, nivolumab, atezolizumab, avelumab and durvalumab. We identified 3 prospective studies, 17 retrospective studies and 4 case series reporting 363 patients in total. Combined data from all three prospective studies provide a prevalence rate of 6.13%. Most patients were males (59.68%) and the vast majority (73%) were on programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors. Most studies report a median time of ≤ 12 weeks from first ICI administration to symptom onset. The main clinical phenotypes reported were: (a) inflammatory arthritis (57.57%), (b) myositis (14.04%) and (c) polymyalgia rheumatica (PMR) (12.12%). A total of 256 patients required steroids (70.52%) and 67 patients (18.45%) were treated with DMARDs. Positive auto-antibodies and family history of any autoimmune disease were present in 18.48% and 19.04% of cases, respectively. Only a few patients (19%) had to discontinue treatment due to musculoskeletal Ir-AE. Two prospective studies show that significantly more patients with musculoskeletal Ir-AE exhibit a favorable oncologic response compared to patients not exhibiting such manifestations whereas retrospective studies show that 77.22% of patients with musculoskeletal Ir-AE have a good tumor response. One out of 15 patients treated with ICI will develop musculoskeletal Ir-AE; in most cases the severity of these manifestations is mild/moderate and usually ICI may be continued. Rheumatologists should familiarize with this new clinical entity and develop relevant therapeutic algorithms.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Farhood B, Najafi M, Mortezaee K (2019) CD8 + cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234:8509–8521PubMed Farhood B, Najafi M, Mortezaee K (2019) CD8 + cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234:8509–8521PubMed
3.
Zurück zum Zitat Tivol EA, Borriello F, Nicola Schweitzer A, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541–547PubMed Tivol EA, Borriello F, Nicola Schweitzer A, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541–547PubMed
4.
Zurück zum Zitat Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141–151PubMed Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141–151PubMed
5.
Zurück zum Zitat Rotte A, Jin JY, Lemaire V (2018) Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol 29:71–83PubMed Rotte A, Jin JY, Lemaire V (2018) Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol 29:71–83PubMed
6.
Zurück zum Zitat Park Y-J, Kuen D-S, Chung Y (2018) Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med 50:109PubMedCentral Park Y-J, Kuen D-S, Chung Y (2018) Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med 50:109PubMedCentral
7.
Zurück zum Zitat Webb ES, Liu P, Baleeiro R, Lemoine NR, Yuan M, Wang Y-H (2018) Immune checkpoint inhibitors in cancer therapy. J Biomed Res 32:317–326PubMed Webb ES, Liu P, Baleeiro R, Lemoine NR, Yuan M, Wang Y-H (2018) Immune checkpoint inhibitors in cancer therapy. J Biomed Res 32:317–326PubMed
8.
Zurück zum Zitat Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168PubMed Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168PubMed
9.
Zurück zum Zitat Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51–60PubMed Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51–60PubMed
10.
Zurück zum Zitat Daoussis D, Kraniotis P, Filippopoulou A, Argiriadi R, Theodoraki S, Makatsoris T, Koutras A, Kehagias I, Papachristou DJ, Solomou A, Haralabos Kalofonos S-NL (2020) MRI study of immune checkpoint inhibitor–induced musculoskeletal manifestations. Myofasciitis is the prominent imaging finding. Rheumatology (Oxford) 59:1041–1050 Daoussis D, Kraniotis P, Filippopoulou A, Argiriadi R, Theodoraki S, Makatsoris T, Koutras A, Kehagias I, Papachristou DJ, Solomou A, Haralabos Kalofonos S-NL (2020) MRI study of immune checkpoint inhibitor–induced musculoskeletal manifestations. Myofasciitis is the prominent imaging finding. Rheumatology (Oxford) 59:1041–1050
11.
Zurück zum Zitat Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C et al (2018) Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 77:393–398PubMed Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C et al (2018) Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 77:393–398PubMed
12.
Zurück zum Zitat Narváez J, Nolla JM, García X, del Muro J, Lluch JAN, Domingo-Domenech E et al (2018) Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev 17:1040–1045PubMed Narváez J, Nolla JM, García X, del Muro J, Lluch JAN, Domingo-Domenech E et al (2018) Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev 17:1040–1045PubMed
13.
Zurück zum Zitat Kostine M, Truchetet M-E, Schaeverbeke T (2019) Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology 58:vii68–vii74PubMedPubMedCentral Kostine M, Truchetet M-E, Schaeverbeke T (2019) Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology 58:vii68–vii74PubMedPubMedCentral
15.
Zurück zum Zitat Daoussis D, Melissaropoulos K, Dimitroulas T, Andreadis H, Christopoulou A, Douganiotis G et al (2020) Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study. Mediterr J Rheumatol 31:239PubMedPubMedCentral Daoussis D, Melissaropoulos K, Dimitroulas T, Andreadis H, Christopoulou A, Douganiotis G et al (2020) Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study. Mediterr J Rheumatol 31:239PubMedPubMedCentral
16.
Zurück zum Zitat Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U (2019) Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol 71:468–475PubMed Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U (2019) Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol 71:468–475PubMed
17.
Zurück zum Zitat Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C et al (2017) Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 82:34–44PubMed Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C et al (2017) Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 82:34–44PubMed
18.
Zurück zum Zitat Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y et al (2018) Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 17:284–289PubMed Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y et al (2018) Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 17:284–289PubMed
19.
Zurück zum Zitat Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U et al (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76:43–50PubMed Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U et al (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76:43–50PubMed
20.
Zurück zum Zitat Belkhir R, Le Burel S, Dunogeant L, Marabelle A, Hollebecque A, Besse B et al (2017) Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis 76:1747–1750PubMed Belkhir R, Le Burel S, Dunogeant L, Marabelle A, Hollebecque A, Besse B et al (2017) Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis 76:1747–1750PubMed
21.
Zurück zum Zitat Mooradian MJ, Nasrallah M, Gainor JF, Reynolds KL, Cohen JV, Lawrence DP et al (2019) Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience. Semin Arthritis Rheum 48:1127–1132PubMed Mooradian MJ, Nasrallah M, Gainor JF, Reynolds KL, Cohen JV, Lawrence DP et al (2019) Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience. Semin Arthritis Rheum 48:1127–1132PubMed
22.
Zurück zum Zitat Smith MH, Bass AR (2019) Arthritis after cancer immunotherapy: symptom duration and treatment response. Arthritis Care Res 71:362–366 Smith MH, Bass AR (2019) Arthritis after cancer immunotherapy: symptom duration and treatment response. Arthritis Care Res 71:362–366
23.
Zurück zum Zitat Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME (2019) Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum 48:736–740PubMed Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME (2019) Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum 48:736–740PubMed
24.
Zurück zum Zitat Lee J, Graham A, Sion A (2019) Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors. J Oncol Pharm Pract 25:1867–1872PubMed Lee J, Graham A, Sion A (2019) Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors. J Oncol Pharm Pract 25:1867–1872PubMed
25.
Zurück zum Zitat Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J et al (2018) Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum 48:553–557PubMedPubMedCentral Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J et al (2018) Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum 48:553–557PubMedPubMedCentral
26.
Zurück zum Zitat Buder-Bakhaya K, Benesova K, Schulz C, Anwar H, Dimitrakopoulou-Strauss A, Weber TF et al (2018) Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother 67:175–182PubMed Buder-Bakhaya K, Benesova K, Schulz C, Anwar H, Dimitrakopoulou-Strauss A, Weber TF et al (2018) Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother 67:175–182PubMed
27.
Zurück zum Zitat Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B et al (2018) Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series. Eur J Cancer 105:88–102PubMed Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B et al (2018) Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series. Eur J Cancer 105:88–102PubMed
28.
Zurück zum Zitat Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210–225PubMed Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210–225PubMed
29.
Zurück zum Zitat Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV et al (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12–23PubMed Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV et al (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12–23PubMed
30.
Zurück zum Zitat Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH (2017) Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open 3:e000412PubMedPubMedCentral Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH (2017) Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open 3:e000412PubMedPubMedCentral
32.
Zurück zum Zitat Liew DFL, Leung JLY, Liu B, Cebon J, Frauman AG, Buchanan RRC (2019) Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy. Int J Rheum Dis 22:297–302PubMed Liew DFL, Leung JLY, Liu B, Cebon J, Frauman AG, Buchanan RRC (2019) Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy. Int J Rheum Dis 22:297–302PubMed
33.
Zurück zum Zitat Kuswanto WF, MacFarlane LA, Gedmintas L, Mulloy A, Choueiri TK, Bermas BL (2018) Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. Semin Arthritis Rheum 47:907–910PubMed Kuswanto WF, MacFarlane LA, Gedmintas L, Mulloy A, Choueiri TK, Bermas BL (2018) Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. Semin Arthritis Rheum 47:907–910PubMed
34.
Zurück zum Zitat Goldstein BL, Gedmintas L, Todd DJ (2014) Concise communication. Arthritis Rheumatol 66:768–769PubMed Goldstein BL, Gedmintas L, Todd DJ (2014) Concise communication. Arthritis Rheumatol 66:768–769PubMed
35.
Zurück zum Zitat Chan MMK, Kefford RF, Carlino M, Clements A, Manoliosz N (2015) Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma case presentation case 1. J Immunother 38:37–39PubMed Chan MMK, Kefford RF, Carlino M, Clements A, Manoliosz N (2015) Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma case presentation case 1. J Immunother 38:37–39PubMed
36.
Zurück zum Zitat Garel B, Kramkimel N, Trouvin AP, Frantz C, Dupin N (2017) Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma. Jt Bone Spine 84:233–234 Garel B, Kramkimel N, Trouvin AP, Frantz C, Dupin N (2017) Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma. Jt Bone Spine 84:233–234
37.
Zurück zum Zitat Weinstock C, Singh H, Maher VE, Kim G, Pazdur R (2017) FDA analysis of patients with baseline autoimmune diseases treated with PD-1/PD-L1 immunotherapy agents. J Clin Oncol 35:3018–3018 Weinstock C, Singh H, Maher VE, Kim G, Pazdur R (2017) FDA analysis of patients with baseline autoimmune diseases treated with PD-1/PD-L1 immunotherapy agents. J Clin Oncol 35:3018–3018
38.
Zurück zum Zitat Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E et al (2019) Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study. Arthritis Rheumatol 71:2100–2111PubMed Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E et al (2019) Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study. Arthritis Rheumatol 71:2100–2111PubMed
39.
Zurück zum Zitat Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D (2019) Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother 68:917–926PubMed Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D (2019) Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother 68:917–926PubMed
40.
Zurück zum Zitat Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F et al (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2:234–240PubMed Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F et al (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2:234–240PubMed
41.
Zurück zum Zitat Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L et al (2017) Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 75:24–32PubMed Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L et al (2017) Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 75:24–32PubMed
42.
Zurück zum Zitat Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L et al (2018) Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 91:21–29PubMed Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L et al (2018) Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 91:21–29PubMed
43.
Zurück zum Zitat Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368–376PubMed Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368–376PubMed
44.
Zurück zum Zitat Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L et al (2018) Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36:1905–1912PubMedPubMedCentral Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L et al (2018) Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36:1905–1912PubMedPubMedCentral
45.
Zurück zum Zitat Lee B, Wong A, Kee D, Neeson P, Shackleton M, McArthur G et al (2016) The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Ann Oncol 27:1174–1177PubMed Lee B, Wong A, Kee D, Neeson P, Shackleton M, McArthur G et al (2016) The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Ann Oncol 27:1174–1177PubMed
46.
Zurück zum Zitat Ruiz-Bañobre J, Pérez-Pampín E, García-González J, Gómez-Caamaño A, Barón-Duarte FJ, López-López R et al (2017) Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. Lung Cancer 108:217–221PubMed Ruiz-Bañobre J, Pérez-Pampín E, García-González J, Gómez-Caamaño A, Barón-Duarte FJ, López-López R et al (2017) Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. Lung Cancer 108:217–221PubMed
47.
Zurück zum Zitat Kyi C, Carvajal RD, Wolchok JD, Postow MA (2014) Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 14(2):35 Kyi C, Carvajal RD, Wolchok JD, Postow MA (2014) Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 14(2):35
48.
Zurück zum Zitat Roberts J, Smylie M, Walker J, Basappa NS, Chu Q, Kolinsky M et al (2019) Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. Clin Rheumatol 38:1513–1519PubMed Roberts J, Smylie M, Walker J, Basappa NS, Chu Q, Kolinsky M et al (2019) Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. Clin Rheumatol 38:1513–1519PubMed
49.
Zurück zum Zitat Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Rottapel R et al (2020) Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev 19:102595PubMed Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Rottapel R et al (2020) Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev 19:102595PubMed
51.
Zurück zum Zitat Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B et al (2020) Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 19:102586PubMed Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B et al (2020) Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 19:102586PubMed
53.
Zurück zum Zitat Matas-García A, Milisenda JC, Selva-O’Callaghan A, Prieto-González S, Padrosa J, Cabrera C et al (2020) Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. Autoimmun Rev 19:102455PubMed Matas-García A, Milisenda JC, Selva-O’Callaghan A, Prieto-González S, Padrosa J, Cabrera C et al (2020) Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. Autoimmun Rev 19:102455PubMed
58.
Zurück zum Zitat Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J et al (2019) Checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis 79:332–338PubMed Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J et al (2019) Checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis 79:332–338PubMed
Metadaten
Titel
Immune checkpoint inhibitor-induced musculoskeletal manifestations
verfasst von
Foteini Angelopoulou
Dimitrios Bogdanos
Theodoros Dimitroulas
Lazaros Sakkas
Dimitrios Daoussis
Publikationsdatum
02.08.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 1/2021
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04665-7

Weitere Artikel der Ausgabe 1/2021

Rheumatology International 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.